Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir
Viruses · 2024
DOI: 10.3390/v16121888 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Hyeonah Byun und 3 weiteren Autor:innen. Beteiligte Einrichtung: HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa. Hauptthemen laut MEDLINE: HIV-1, HIV Reverse Transcriptase, Drug Resistance, Viral, Mutation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Poliomyelitis Research Foundation.
Abstract (Originalsprache)
Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL. Prevalent single and combinations of NRTI-resistant mutations were selected from a routine HIV-1 genotypic drug resistance testing database and introduced into HIV-1 subtype C-like pseudoviruses, which were then tested for ISL susceptibility. Single NRTI-resistant mutations were susceptible or showed only a low level of resistance to ISL. This included thymidine analogue mutations (TAMs, i.e., M41L, D67N, K70R, T215FY, and K219EQ) and non-TAMs (i.e., A62V, K65R, K70ET, L74IV, A114S, Y115F, and M184V). Combinations of M184V with one or more additional NRTI-resistant mutations generally displayed reduced ISL susceptibilities. This was more prominent for combinations that included M184V+TAMs, and particularly M184V+TAM-2 mutations. Combinations that included M184V+K65R did not impact significantly on ISL susceptibility. Our study suggests that ISL would be effective in treating people living with HIV (PLWH) failing tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) or TDF/emtricitabine (FTC)-containing regimens, but would be less effective in PLH failing zidovudine (AZT) with 3TC or FTC-containing regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
- National Priority Programme, National Health Laboratory Service, Johannesburg 2192, South Africa.
- Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
ORCID-Profile: Kim Steegen, Adriaan Erasmus Basson
Förderung
- Poliomyelitis Research Foundation
Zitieren
APA
Byun, H., Papathanasopoulos, M. A., Steegen, K., & Basson, A. E. (2024). Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. https://doi.org/10.3390/v16121888
Vancouver
Byun H, Papathanasopoulos MA, Steegen K, Basson AE. Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir. Viruses. 2024. doi:10.3390/v16121888
BibTeX
@article{Byun2024,
author = {Byun, Hyeonah and Papathanasopoulos, Maria Antonia and Steegen, Kim and Basson, Adriaan Erasmus},
title = {Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121888}
}
EUVIMED